Vivo Capital Llc
SEC-registered
Private Fund Manager · Mid-sized ($1B–$10B)
CRD 159868
· SEC file 801-79829
· Palo Alto, CA
· www.linkedin.com
☆ Save with Pro
ADV data as of Mar 31, 2026
- Regulatory AUM
- $6.1B
- Discretionary
- $6.1B
- Clients
- 16
- Avg AUM / client
- $381M
- Accounts
- 16
- Employees
- 62
AUM over time
$938M
$6.5B
May 2014
Dec 2025
Annual snapshots from Form ADV filings · as of Mar 31, 2026
Investments (13F portfolio — 46 positions, $1,202,954,264)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Erasca Inc | Common | $196,610,946 | 12,151,480 | 16.3% | 3.23% |
| 2 | Praxis Precision Medicines | Common | $109,188,580 | 338,895 | 9.08% | 1.79% |
| 3 | Terns Pharmaceuticals Inc | Common | $70,350,517 | 1,334,418 | 5.85% | 1.15% |
| 4 | Trevi Therapeutics Inc | Common | $60,779,389 | 5,094,668 | 5.05% | 1.0% |
| 5 | Dbv Technologies Sa | SPONSORED ADS | $55,725,516 | 2,667,569 | 4.63% | 0.91% |
| 6 | Compass Therapeutics Inc | Common | $50,495,515 | 9,545,466 | 4.2% | 0.83% |
| 7 | Tango Therapeutics Inc | Common | $45,077,998 | 2,154,780 | 3.75% | 0.74% |
| 8 | Sab Biotherapeutics Inc | Common | $43,738,600 | 11,420,000 | 3.64% | 0.72% |
| 9 | Corvus Pharmaceuticals Holdings | Common | $41,049,088 | 2,805,816 | 3.41% | 0.67% |
| 10 | Bright Minds Biosciences Inc | Common | $40,656,841 | 557,172 | 3.38% | 0.67% |
| 11 | Sinovac Biotech Ltd. | SHS | $38,192,410 | 5,903,000 | 3.17% | 0.63% |
| 12 | Dianthus Therapeutics Inc | Common | $29,707,512 | 353,998 | 2.47% | 0.49% |
| 13 | Dyne Therapeutics Inc | Common | $28,236,859 | 1,557,466 | 2.35% | 0.46% |
| 14 | Abivax Sa Adr | SPONSORED ADS | $26,672,668 | 239,539 | 2.22% | 0.44% |
| 15 | Minerva Neurosciences Inc | Common | $26,044,551 | 4,322,747 | 2.17% | 0.43% |
| 16 | Aclaris Therapeutics, Inc. | Common | $24,999,998 | 6,666,666 | 2.08% | 0.41% |
| 17 | Oric Pharmaceuticals Inc | Common | $23,424,119 | 1,848,786 | 1.95% | 0.38% |
| 18 | Alto Neuroscience Inc | Common | $23,279,186 | 1,035,551 | 1.94% | 0.38% |
| 19 | Sensei Biotherapeutics Inc | Common | $22,758,070 | 722,020 | 1.89% | 0.37% |
| 20 | Arrivent Bio Pharma Inc | Common | $20,438,082 | 885,916 | 1.7% | 0.34% |
| 21 | Lb Pharmaceuticals Inc | Common | $19,728,000 | 800,000 | 1.64% | 0.32% |
| 22 | Veradermics Inc | Common | $18,945,000 | 300,000 | 1.57% | 0.31% |
| 23 | Camp4 Therapeutics Inc | Common | $18,727,365 | 4,246,568 | 1.56% | 0.31% |
| 24 | Moonlake Immunotherapeutics | Common | $18,640,000 | 1,000,000 | 1.55% | 0.31% |
| 25 | Design Therapeutics Inc | Common | $17,161,288 | 1,612,903 | 1.43% | 0.28% |
Top 25 of 46 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 16 | $6.1B | 100.0% |
Private funds (15)
Reported in Form ADV Section 7.B.(1), filing of Sep 2024 · $6.0B combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Vivo Capital Fund Ix, L.P. | Private Equity Fund | Delaware | $2.6B | 46 |
| Vivo Opportunity Fund Holdings, L.P. master | Other Private Fund | Delaware | $1.0B | 65 |
| Vivo Capital Fund Viii, L.P. | Private Equity Fund | Delaware | $609M | 59 |
| Vivo Capital Fund X, L.P. | Private Equity Fund | Delaware | $548M | 16 |
| Vivo Innovation Fund Ii Holdings, L.P master | Venture Capital Fund | Delaware | $340M | 35 |
| Vivo Super Viii Limited | Venture Capital Fund | Cayman Islands | $225M | 6 |
| Vivo Co Invest (C), L.P. | Private Equity Fund | Delaware | $150M | 2 |
| Vivo Asia Opportunity Fund Holdings, L.P. master | Other Private Fund | Cayman Islands | $118M | 21 |
| Vivo Capital Surplus Fund Viii, L.P. | Private Equity Fund | Delaware | $84.1M | 9 |
| Vivo Opportunity Co Invest, L.P. | Other Private Fund | Delaware | $81.5M | 2 |
| Vivo Panda Fund, Lp | Venture Capital Fund | Delaware | $74.7M | 12 |
| Vivo Ventures Fund Vii, Lp | Venture Capital Fund | Delaware | $51.3M | 45 |
| Vivo Co Invest (S), L.P. | Venture Capital Fund | Delaware | $50.0M | 1 |
| Vivo Ventures Fund Cayman Vii, Lp | Venture Capital Fund | Cayman Islands | $39.7M | 13 |
| Vivo Ventures Vii Affiliates Fund, Lp | Venture Capital Fund | Delaware | $1.2M | 33 |
People (7)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Engleman, Edgar, George | Managing Partner | Jun 2005 (21y) | 10% – 25% | |
| Kung, Frank, Fang Chien | Managing Partner | Jun 2005 (21y) | 25% – 50% | |
| Sheu, Cinthia, Hui Hsin | Partner / Chief Operating Officer | Apr 2008 (18y) | Less than 5% | |
| Fu, Shan, (Nmn) | Managing Partner | Jan 2015 (12y) | 10% – 25% | |
| Wu, Zhanping, (Nmn) | Partner / General Counsel / Chief Compliance Officer | Nov 2019 (7y) | Less than 5% | |
| Chang, Michael, J. | Managing Partner | Jan 2021 (6y) | 5% – 10% | |
| Nielsen, Jack, Bech | Managing Partner | Jan 2021 (6y) | 5% – 10% |
Undisclosed: 0% – 45% of the firm is not attributable from the filed Schedule A bands.
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (15, $6.0B gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Vivo Capital Fund Ix, L.P. | Private Equity Fund | $2.6B | $25.0M | 46 |
| Vivo Opportunity Fund Holdings, L.P. | Other Private Fund | $1.0B | $0 | 65 |
| Vivo Capital Fund Viii, L.P. | Private Equity Fund | $609M | $250K | 59 |
| Vivo Capital Fund X, L.P. | Private Equity Fund | $548M | $25.0M | 16 |
| Vivo Innovation Fund Ii Holdings, L.P | Venture Capital Fund | $340M | $0 | 35 |
| Vivo Super Viii Limited | Venture Capital Fund | $225M | $10.0K | 6 |
| Vivo Co Invest (C), L.P. | Private Equity Fund | $150M | $0 | 2 |
| Vivo Asia Opportunity Fund Holdings, L.P. | Other Private Fund | $118M | $0 | 21 |
| Vivo Capital Surplus Fund Viii, L.P. | Private Equity Fund | $84.1M | $7.0M | 9 |
| Vivo Opportunity Co Invest, L.P. | Other Private Fund | $81.5M | $0 | 2 |
| Vivo Panda Fund, Lp | Venture Capital Fund | $74.7M | $2.0M | 12 |
| Vivo Ventures Fund Vii, Lp | Venture Capital Fund | $51.3M | $500K | 45 |
| Vivo Co Invest (S), L.P. | Venture Capital Fund | $50.0M | $0 | 1 |
| Vivo Ventures Fund Cayman Vii, Lp | Venture Capital Fund | $39.7M | $750K | 13 |
| Vivo Ventures Vii Affiliates Fund, Lp | Venture Capital Fund | $1.2M | $25.0K | 33 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/31/2026 | 5.21 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports having custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 31, 2026.
View current Form ADV (SEC/IAPD) ↗